The late phase of sepsis is characterized by an increased microbiological burden and death rate

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Otto, Gordon P ^a   Sossdorf, Maik ^a   Claus, Ralf A ^a   Rödel, Jürgen ^a   Menge, Katja ^a   Reinhart, Konrad ^a   Bauer, Michael ^a   Riedemann, Niels C ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; ANIDULAFUNGIN; ANSAMYCIN DERIVATIVE; CARBAPENEM DERIVATIVE; CASPOFUNGIN; CEPHALOSPORIN DERIVATIVE; FLUCONAZOLE; FOLIC ACID ANTAGONIST; GLYCYLCYCLINE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LINCOSAMIDE; MACROLIDE; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PROCALCITONIN; PYRROLE; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN; VORICONAZOLE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; CANDIDA; DIALYSIS; DISEASE COURSE; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME; GERMANY; MEDICAL AUDIT; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANTI-INFECTIVE AGENTS; FEMALE; GERMANY; HOSPITAL MORTALITY; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 79960653221     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10332     Document Type: Article

References (25)

1. Angus DC. The lingering consequences of sepsis: a hidden public health disaster?. JAMA 2010, 304:1833-1834. 10.1001/jama.2010.1546, 20978262.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
3. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-1128. 10.1097/00003246-199607000-00010, 8674323.
4. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000, 26(Suppl 1):S124-128.
5. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009, 361:1570-1583. 10.1056/NEJMra0901217, 19828534.
6. Hotchkiss RS, Opal S. Immunotherapy for sepsis a new approach against an ancient foe. N Engl J Med 2010, 363:87-89. 10.1056/NEJMcibr1004371, 20592301.
7. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends Immunol 2003, 24:254-258. 10.1016/S1471-4906(03)00079-6, 12738419.
8. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, Allombert C, Mougin B, Malcus C, Poitevin-Later F, Lepape A, Monneret G. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010, 34:358-363. 10.1097/SHK.0b013e3181dc0977, 20220566.
9. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524. 10.1038/nm0503-517, 12724763.
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
12. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Critical Care Medicine 1998, 26:1793-1800. 10.1097/00003246-199811000-00016, 9824069.
13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
14. Westh H, Lisby G, Breysse F, Boddinghaus B, Chomarat M, Gant V, Goglio A, Raglio A, Schuster H, Stuber F, Wissing H, Hoeft A. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect 2009, 15:544-551. 10.1111/j.1469-0691.2009.02736.x, 19392905.
15. Ehrenstein BP, Ehrenstein V, Henke C, Linde HJ, Salzberger B, Scholmerich J, Gluck T. Risk factors for negative blood cultures in adult medical inpatients a retrospective analysis. BMC Infect Dis 2008, 8:148. 10.1186/1471-2334-8-148, 2582035, 18957115.
16. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124. 10.1056/NEJMoa071366, 18184957.
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
18. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007, 33:396-399. 10.1007/s00134-007-0556-8, 17325833.
19. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169.
20. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998, 351:929-933.
21. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC, Abraham E, Bellamy P, Cryer H, Busuttil R, Winston D, Perry C, Wunderink R, Leeper KV, Jones C, Silverman H, Martin M, Tuma P, Baird I, Brooks J, Baird R, Wenzel RP, Perl TM, et al. TNF-α MAb Sepsis Study Group Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995, 273:934-941. 10.1001/jama.273.12.934, 7884952, TNF-α MAb Sepsis Study Group.
22. Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what's next?. JAMA 2003, 290:256-258. 10.1001/jama.290.2.256, 12851282.
23. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648. 10.1164/rccm.200903-0363OC, 19590022.
24. Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, Root R, Wilson J. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 1998, 178:1075-1080. 10.1086/515694, 9806037.
25. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997, 157:389-393. 10.1001/archinte.157.4.389, 9046890.